Ionis’ Tegsedi (inotersen) Receives FDA Approval for Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults

 Ionis’ Tegsedi (inotersen) Receives FDA Approval for Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults

Ionis’ Tegsedi (inotersen) Receives FDA Approval for Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults

Shots:

  • The approval is based on P-III NEURO-TTR study trial assessing Tegsedi vs PBO in 172 patients in ratio (2:1) with hATTR amyloidosis with symptoms of polyneuropathy
  • The study resulted in effective results in measures of neuropathy and QoL while measuring with a Neuropathy Impairment Score +7 (mNIS+7) & Norfolk QOL-DN total score with 80% reduction in TTR
  • Tegsedi (inotersen) is a qw SC RNA-targeting drug used for the reduction in the production of TTR protein and has also received EU and Health Canada approval for 1 or stage 2 polyneuropathy in adult patients with hATTR. In April, 2018 Ionis granted Akcea worldwide rights to commercialize Tegsedi

Click here to read full press release/ article | Ref: Ionis | Image: USA today

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post